clinical trial · NCT06028594
Compassionate Use of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria
Paroxysmal Nocturnal HemoglobinuriaPozelimabCemdisiran
brief summary
This program is designed to provide access to pozelimab and cemdisiran and document the long-term safety of pozelimab and cemdisiran combination therapy in patients with paroxysmal nocturnal hemoglobinuria (PNH). PNH is a rare immune disease that causes red blood cells in your body to break apart.
started
—
primary completion
—
completion
—
last updated
Oct 20, 2025
official title
An Expanded Access Program of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol